Literature DB >> 8107658

Prospects for pirarubicin.

A A Miller1, E Salewski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8107658     DOI： 10.1002/mpo.2950220410

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  14 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy.

Authors:  Liang Wang; Panpan Liu; Xiaoqin Chen; Qirong Geng; Yue Lu
Journal:  Med Oncol       Date:  2011-08-30       Impact factor: 3.064

3.  Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

Authors:  Hideko Goto; Hisashi Tsurumi; Masao Takemura; Yoriko Ino-Shimomura; Senji Kasahara; Michio Sawada; Toshiki Yamada; Takeshi Hara; Kenji Fukuno; Naoe Goto; Masataka Okuno; Tsuyoshi Takami; Mitsuru Seishima; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-21       Impact factor: 4.553

4.  Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.

Authors:  Takeshi Hara; Hisashi Tsurumi; Naoe Goto; Jun-ichi Kitagawa; Nobuhiro Kanemura; Takeshi Yoshikawa; Senji Kasahara; Hideko Goto; Kenji Fukuno; Toshiki Yamada; Michio Sawada; Ichiro Yasuda; Naoki Katsumura; Takeshi Takahashi; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

5.  Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.

Authors:  Takeshi Hara; Hisashi Tsurumi; Naoe Goto; Nobuhiro Kanemura; Takeshi Yoshikawa; Senji Kasahara; Toshiki Yamada; Michio Sawada; Hideko Goto; Kenji Fukuno; Jun-Ichi Kitagawa; Ichiro Yasuda; Naoki Katsumura; Masao Takemura; Takeshi Takahashi; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-21       Impact factor: 4.553

6.  Clinical significance of jejunoileal involvement of non-Hodgkin's lymphoma detected by double-balloon enteroscopy.

Authors:  Takashi Ibuka; Hisashi Tsurumi; Hiroshi Araki; Takeshi Hara; Fumito Onogi; Naoe Goto; Yasushi Kojima; Nobuhiro Kanemura; Makoto Shiraki; Senji Kasahara; Masahito Shimizu; Kengo Ogawa; Soranobu Ninomiya; Takayuki Nakanishi; Tomohiro Kato; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2013-02-02       Impact factor: 2.490

7.  Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).

Authors:  Jun-ichi Kitagawa; Takeshi Hara; Hisashi Tsurumi; Naoe Goto; Nobuhiro Kanemura; Takeshi Yoshikawa; Senji Kasahara; Toshiki Yamada; Michio Sawada; Takeshi Takahashi; Masahito Shimizu; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-01       Impact factor: 4.553

8.  Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.

Authors:  Liang Wang; Zhong-jun Xia; Hui-qiang Huang; Yue Lu; Yu-jing Zhang
Journal:  Int J Hematol       Date:  2012-09-16       Impact factor: 2.490

9.  Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.

Authors:  Hisashi Tsurumi; Toshiki Yamada; Michio Sawada; Senji Kasahara; Nobuhiro Kanemura; Yasushi Kojima; Kenji Fukuno; Takeshi Hara; Masanao Saio; Takeshi Takahashi; Masami Oyama; Keiya Ozawa; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-27       Impact factor: 4.553

10.  3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis.

Authors:  Hiroaki Araie; Ippei Sakamaki; Yasufumi Matsuda; Katsunori Tai; Satoshi Ikegaya; Kazuhiro Itoh; Shinji Kishi; Kana Oiwa; Miyuki Okura; Toshiki Tasaki; Naoko Hosono; Takanori Ueda; Takahiro Yamauchi
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.